References
- Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–1812.
- Stupka JE, Mortensen EM, Anzueto A, et al. Community-acquired pneumonia in elderly patients. Aging health. 2009;5(6):763–774.
- Broulette J, Yu H, Pyenson B, et al. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013;6(8):494–503.
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
- Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–55.
- Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–59.
- National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. Clinical guideline [CG191]; 2014. [cited 2018 Dec 1]. Available from: https://www.nice.org.uk/guidance/cg191
- Wunderink RG, Yin Y. Antibiotic resistance in community-acquired pneumonia pathogens. Semin Respir Crit Care Med. 2016;37(6):829–838.
- Haran JP, Volturo GA. Macrolide resistance in cases of community-acquired bacterial pneumonia in the emergency department. J Emerg Med. 2018;55:347–353.
- Projan SJ. Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6(5):427–430.
- Kraus CN. Low hanging fruit in infectious disease drug development. Curr Opin Microbiol. 2008;11(5):434–438.
- Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38(9):1279–1286.
- Sader HS, Biedenbach DJ, Paukner S, et al. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(3):1619–1623.
- Paukner S, Sader HS, Ivezic-Schoenfeld Z, et al. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013;57(9):4489–4495.
- Novak R. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci. 2011;1241:71–81.
- Nabriva Therapeutics. Pipeline and research; 2018. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/pipeline-research
- Sader HS, Paukner S, Ivezic-Schoenfeld Z, et al. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012;67(5):1170–1175.
- Eyal Z, Matzov D, Krupkin M, et al. Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus. Proc Natl Acad Sci U S A. 2015;112(43):E5805–5814.
- Paukner S, Flamm RK, Arends SJR, et al. In vitro activity of lefamulin against a collection of respiratory pathogens from pediatric patients in US (SENTRY surveillance 2015). ASM Microbe; 2017; Poster 24. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-lefamulin-against-respiratory-pathogens-in-pediatric-patients.pdf
- Jacobsson S, Paukner S, Golparian D, et al. In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017;61(11).
- Paukner S, Flamm RK, Arends SJR, et al. In vitro antibacterial activity of lefamulin against S. aureus collected from hospitalized patients with bacterial pneumonia in US. ASM Microbe; 2017; Poster 344. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-usa-lefamulin-activity-s-aureus-in-cabp.pdf
- Paukner S, Sader HS, Flamm RK, et al. In vitro activity of lefamulin against S. aureus from hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP) patients in Europe. ECCMID; 2017; Poster P1332. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-%20lefamulin-activity-s-aureus-hap-cap-patients-in-europe.pdf
- Paukner S, Flamm RK, Streit JM, et al. In vitro activity of lefamulin against S. aureus collected from hospitalized patients with bacterial pneumonia (CAP) in Europe. ECCMID; 2017; Poster P1333. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-%20lefamulin-activity-s-aureus-hospitalized-cap-patients-europe.pdf
- Paukner S, Flamm RK, Schuchert J, et al. In vitro activity of lefamulin against S. aureus collected worldwide from hospitalized patients with bacterial pneumonia. ID Week; 2017; Poster 1218. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/Poster_1218_ID%20Week%202017_Lefamulin%20S%20aureus%20pneumonia_FINAL.pdf
- Sader HS, Mendes RE, Rhomberg PR, et al. Antimicrobial activity of lefamulin, an investigational pleuromutilin antibiotic, against Staphylococcus aureus strains with decreased susceptibility to vancomycin. ICAAC/ICC; 2015; Poster C-559. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2015-%20pleuromutilin-antibiotic-against-staphylococcus%20aureus-&-vancomycin.pdf
- Mendes RE, Farrell DJ, Flamm RK, et al. In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. Antimicrob Agents Chemother. 2016;60(7):4407–4411.
- Paukner S, Gassner G, Gruss A. In vitro bactericidal activity of lefamulin against Streptococcus pneumoniae isolates. ECCMID; 2018; Poster P0250. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/0/Nabriva/Posters/ECCMID_2018/ECCMID%202018%20Kill%20curve%20data%20strep_Final.pdf
- Paukner S, Streit JM, Flamm RK, et al. In vitro activity of lefamulin against bacterial pathogens commonly causing acute bacterial skin and skin structure infections (ABSSSI) and bloodstream infections (BSI): global SENTRY surveillance 2016. ASM Microbe; 2018; Poster 643. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/0/Assets/ASM_Microbe_SENTRY%202016%20ABSSSI_P643.pdf
- Mendes RE, Doyle TB, Paukner S, et al. Molecular characterization of resistance mechanisms associated with pleuromutilins among gram-positive clinical isolates from the worldwide SENTRY surveillance studies for lefamulin. ASM Microbe; 2018; Poster 642. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/0/Assets/ASM_Microbe_SENTRY%202015-2016%20resistance%20mechanisms_P642.pdf
- Paukner S, Sader HS, Streit JM, et al. In vitro activity of lefamulin against bacterial pathogens collected from patients with community-acquired bacterial pneumonia (CABP) – SENTRY 2015 US data. ASM Microbe; 2017; Poster 85. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-lefamulin-cabp-patients-2015-sentry-us-data.pdf
- Paukner S, Sader HS, Streit JM, et al. In vitro activity of lefamulin against bacterial pathogens commonly causing pneumonia collected from patients in Asia (2015). ASM Microbe; 2017; Poster 345. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-asia-lefamulin-against-bacterial-microbes-pneumonia.pdf
- Paukner S, Sader HS, Streit JM, et al. In vitro activity of lefamulin against bacterial pathogens commonly causing community-acquired bacterial pneumonia (CAP): 2015 SENTRY data from Europe. ECCMID; 2017; Poster P1331. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-%20lefamulin-activity-against-bacterial-cabp.pdf
- Paukner S, Sader HS, Streit JM, et al. In vitro activity of lefamulin against a global collection of bacterial pathogens commonly causing community-acquired bacterial pneumonia (CABP) - SENTRY 2015. ID Week; 2017; Poster 1220. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/Poster_1220_ID%20Week%202017_Lefamulin%20CABP%20pathogens_Final.pdf
- Waites KB, Crabb DM, Duffy LB, et al. In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob Agents Chemother. 2017;61(2):pii: e02008-16.
- Jensen JS, Paukner S. Lefamulin is highly active in vitro against multi-drug resistant Mycoplasma genitalium strains. ECCMID; 2017; Poster P1335. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-%20lefamulin-and-mycoplasma-genitalium-strains.pdf
- Wicha WW, Paukner S, Strickmann DB, et al. Pharmacokinetics-pharmacodynamics of lefamulin in a neutropenic murine lung infection model. ICAAC/ICC; 2015; Poster A-037. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2015-%20pharmacokinetics-pharmacodynamics-lefamulin-in-lung-infection.pdf
- Wicha WW, Kappes CB, Fischer E. Efficacy of lefamulin against Staphylococcus aureus-induced bacteremia in a neutropenic and immunocompetent murine model. ID Week; 2017; Poster 1509. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/Poster_1509_ID%20Week%202017_Vivo%20Bacteremia_Final.pdf
- Wicha WW, Henson C, Webbley K. Tissue distribution of [14C]-lefamulin in the urogenital tract in rats. ECCMID; 2018; Poster 0257. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/0/Nabriva/Posters/ECCMID_2018/ECCMID%202018%20QWBA-STI_Final.pdf
- Zhang L, Bhavnani SM, Ambrose PG, et al. Population pharmacokinetic analysis for lefamulin plasma and epithelial lining fluid exposures using data from healthy subjects. ECCMID; 2017; Poster EP0351. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-pharmacokinetic-for-lefamulin-plasma-&-epithelial-lining-fluid-healthy-subjects.pdf
- Zeitlinger M, Schwameis R, Burian A, et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother. 2016;71(4):1022–1026.
- Zhang L, Bhavnani SM, Ambrose PG, et al. Population pharmacokinetic analysis for lefamulin using phase 1 data and assessment of optimal PK sampling strategies for a phase 3 community-acquired bacterial pneumonia study. ID Week; 2016; Poster 1944. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2016-%20pharmacokinetic-analysis-for-lefamulin-phase%203-cabp-study.pdf
- Nabriva Therapeutics. Bioavailability and pharmacokinetics of lefamulin when administered to fed and fasted healthy subjects. In: ClinicalTrials.gov [Internet]. NLM Identifier: NCT02557789. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Nov 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02557789
- Wicha WW, Seltzer E, Prince WT, et al. Pharmacokinetics and safety of an oral, immediate-release (IR) tablet formulation of lefamulin in fed and fasted healthy subjects. ECCMID; 2017; Poster P1336. [cited 2018 Dec 3]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2017-%20pharmacokinetics-immediate-release-tablet-%20p1336-be-study.pdf
- Bhavnani SM, Ambrose PG, Wicha WW, et al. Pharmacokinetic-pharmacodynamic target attainment analyses supporting lefamulin dose selection for the treatment of patients with community-acquired pneumonia. IDWeek; 2016; Poster 793. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2016-%20pharmacokinetic-pharmacodynamic-for-oral-lefamulin-dose-in-cabp.pdf
- Bhavnani SM, Zhang L, Rubino CM, et al. Pharmacokinetic-pharmacodynamic target attainment analyses to support oral lefamulin dose selection in the treatment of patients with community-acquired bacterial pneumonia. ID Week; 2016; Poster 1976. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2016-%20pharmacokinetic-pharmacodynamic-for-oral-lefamulin-dose-in-cabp.pdf
- Prince WT, Ivezic-Schoenfeld Z, Lell C, et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013;57(5):2087–2094.
- Nabriva Therapeutics. Study comparing the safety and efficacy of two doses of BC-3781 vs vancomycin in patients with acute bacterial skin and skin structure infection (ABSSSI). In: ClinicalTrials.gov [Internet]. NLM Identifier: NCT01119105. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Nov 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01119105
- Rubino CM, Xue B, Bhavnani SM, et al. Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59(1):282–288.
- Nabriva Therapeutics. Study to compare lefamulin to moxifloxacin (with or without linezolid) for the treatment of adults with pneumonia (LEAP). In: ClinicalTrials.gov [Internet]. NLM Identifier: NCT02559310. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Nov 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02559310
- Nabriva Therapeutics. Study to compare lefamulin to moxifloxacin for the treatment of adults with pneumonia (LEAP2). In: ClinicalTrials.gov [Internet]. NLM Identifier: NCT02813694. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Nov 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02813694
- File T, Goldberg L, Das A, et al. Lefamulin demonstrates favorable safety and tolerability in adults with community-acquired bacterial pneumonia (CABP) in the phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) study. ECCMID; 2018; Poster P0276. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/0/Nabriva/Posters/ECCMID_2018/ECCMID%202018%20LEAP1%20Safety_Final.pdf
- Nabriva Therapeutics. Nabriva therapeutics announces positive topline results from global, phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia; 2017. [cited 2018 Dec 1]. Available from: http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-announces-positive-topline-results-global
- Nabriva Therapeutics. Lefamulin Evaluation Against Pneumonia (LEAP 1) phase 3 topline results; 2017. [cited 2018 Dec 1]. Available from: https://investors.nabriva.com/static-files/6e30369b-5ef7-4baf-b461-8ae5580771c1
- File T, Goldberg L, Das A, et al. Lefamulin is noninferior to moxifloxacin in adults with community-acquired bacterial pneumonia: phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) study. ECCMID; 2018; Poster 0277. [cited 2018 Dec 1]. Available from: https://www.nabriva.com/Portals/0/Nabriva/Posters/ECCMID_2018/ECCMID%202018%20LEAP1%20Primary_Final.pdf
- Nabriva Therapeutics. Nabriva therapeutics announces positive topline results from pivotal phase 3 clinical trial of oral lefamulin for the treatment of community-acquired bacterial pneumonia; 2018. [cited 2018 Dec 1]. Available from: https://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-announces-positive-topline-results-pivotal
- Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018;38(9):935–946.